September 15, 2022

Imbria Pharmaceuticals to Participate in the UBS Biotechnology Private Company Virtual Symposium

August 26, 2022

Imbria Presents Positive Clinical Data for Ninerafaxstat from IMPROVE-DiCE at the European Society of Cardiology Congress 2022

August 22, 2022

Imbria Pharmaceuticals to Present Phase 2a Data from the Ninerafaxstat Program at the European Society of Cardiology Congress 2022

March 24, 2022

Imbria Appoints John Young to its Board of Directors

March 22, 2022

Imbria Pharmaceuticals to Participate at SVB Leerink Biopharma Private Company Connect

March 10, 2022

Imbria Pharmaceuticals Strengthens Executive Leadership Team with New Appointments

July 19, 2021

Imbria Pharmaceuticals Announces initiation of enrollment in IMPROVE-HCM, a Phase 2 Study Investigating the safety, tolerability, and efficacy of IMB-1018972 (IMB-101) in patients with non-obstructive hypertrophic cardiomyopathy

June 22, 2021

Imbria Pharmaceuticals announces enrolment of the first 10 patients in IMPROVE-DiCE, an exploratory Phase 2 study investigating the impact of IMB-1018972 on cardiac energetics, metabolism and function in patients with type 2 diabetes

May 17, 2021

Imbria Pharmaceuticals Presents Phase 1 and Preclinical Data of IMB-1018972 (IMB-101), an Investigational Cardiac Mitotrope, at the American College of Cardiology 70th Annual Scientific Session & Expo